title: Quetiapine for tic disorder: a case report.
abstract: Tic disorders happen in nearly 20 per cent of children. There is no "best drug" to treat this illness. Potent antipsychotics e.g. haloperidol and pimozide, are the most effective drugs but their limitations are their extrapyramidal side effects (EPS). Risperidone has been proved on efficacy for tic disorders but EPS still remain, even though it was claimed to be less. Thus, quetiapine, a newer atypical neuroleptic with the same action as risperidone and produces fewer EPS, was included in this study.
  
  
  OBJECTIVE
  To study the efficacy and side effects of quetiapine in tic disorders.
  
  
  METHODS
  A case report of a 19-year-old female patient with tic disorder who had taken haloperidol 2 mg/d with benzhexol HCl 2-4 mg/d, then switched to risperidone 1.5 mg/d with benzhexol HCl 4 mg/d because of acute dystonia and oculogyric. She was then prescribed quetiapine, 50 mg/d as a starting dose without benzhexol HCI, because of the remaining symptoms and EPS. The severity of the symptoms was assessed monthly using the Behavior Rating Scale. The dose was increased by 50 mg/d weekly for a better outcome.
  
  
  RESULTS
  The tic was improved after the first week and disappeared for three weeks with 150 mg/d of quetiapine. However, the tic returned again, but less frequently (20%). Thus, the dose was stepped up to 200 mg/d. One week later, the patient reported that the tic has disappeared.
  
  
  CONCLUSIONS
  Quetiapine showed the efficacy and fewest EPS in this patient. However, a further clinically controlled trial must be carried out before quetiapine can become the first-line treatment for tic disorders.
authors.affiliation: Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Thailand.
authors.forename: T
authors.initials: T
authors.lastname: Chan-Ob
authors.forename: N
authors.initials: N
authors.lastname: Kuntawongse
authors.forename: V
authors.initials: V
authors.lastname: Boonyanaruthee
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000627:therapeutic use; D013981:Tic Disorders / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D006220:Haloperidol; D018967:Risperidone